Short Interest in StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) Expands By 44.7%

StageZero Life Sciences Ltd. (OTCMKTS:SZLSFGet Rating) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 17,800 shares, a growth of 44.7% from the April 15th total of 12,300 shares. Based on an average trading volume of 23,600 shares, the days-to-cover ratio is presently 0.8 days.

StageZero Life Sciences stock remained flat at $$0.08 during mid-day trading on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.57 and a quick ratio of 0.41. The stock has a fifty day moving average of $0.11 and a 200 day moving average of $0.18. StageZero Life Sciences has a 1-year low of $0.07 and a 1-year high of $0.57.

About StageZero Life Sciences (Get Rating)

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood.

See Also

Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.